-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 V4IxUQodfk6HlDW+aGgOoVXx6SPz3WR74JR2NCui36Sixc7scoWGJXrh8uqNl9Ok
 tp1gcJgWfvcGqO7YvlG4Pw==

<SEC-DOCUMENT>0001144204-07-066675.txt : 20071210
<SEC-HEADER>0001144204-07-066675.hdr.sgml : 20071210
<ACCEPTANCE-DATETIME>20071210161312
ACCESSION NUMBER:		0001144204-07-066675
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071210
FILED AS OF DATE:		20071210
DATE AS OF CHANGE:		20071210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071295887

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v096825_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      December 10, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font face="Wingdings">x</font>&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font>&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><IMG SRC="v096825_logo.jpg"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      BIOPHARMACEUTICALS PRESENTS DATA REGARDING ITS HEPATITIS C VIRUS SMALL MOLECULE
      PROGRAM AT HEP DART 2007 - AN INTERNATIONAL SCIENTIFIC CONFERENCE ON VIRAL
      HEPATITIS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, December 10, 2007</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) announced today that it will
      make two scientific presentations related to its pre-clinical Hepatitis C virus
      (HCV) small molecule program at HEP DART 2007, an international scientific
      conference on viral hepatitis being held this week in Lahaina,
      Hawaii.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      poster
      presentation entitled </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;Mechanistic
      Characterization of Potent Small Molecule HCV Inhibitors that Target NS5A&#8221;
</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">describes
      a family of small molecule inhibitors of HCV that target the NS5A viral protein.
      Potency of these compounds was evaluated in a replicon assay, which is known
      to
      have good correlation with clinical efficacy and is the current gold standard
      for pre-clinical testing of inhibitors of HCV. In the replicon assay, the
      compounds had single-digit nM (nanomolar) and low double-digit nM potencies
      against genotypes 1b and 1a, respectively. These genotypes constitute the
      majority of HCV infections in the U.S. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New
      data
      presented further substantiate NS5A as the target of these compounds. The new
      data includes results from </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>in
      vitro</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      binding
      to NS5A, resistance selection, molecular genetic and molecular modeling studies.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NS5A
      is a
      viral protein that is essential for RNA production and is distinct from the
      protease and polymerase - the viral targets of the more advanced HCV inhibitors
      in clinical development. As such, inhibitors of NS5A are considered promising
      candidates for the treatment of HCV. As a relatively new target, only one NS5A
      inhibitor has entered clinical trials to date - A831 - which is presently in
      a
      Phase 1 clinical trial. A831 was developed by Arrow Therapeutics, which was
      recently acquired by AstraZeneca. The Company&#8217;s compounds presented appear to be
      significantly more potent than A831 in the replicon assay.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      second
      poster presentation entitled </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;Pharmacologic
      Evaluation of Novel Small Molecule HCV Inhibitors Affecting NS5A-dependent
      Functions&#8221; </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">describes
      the results of studies on the potency, specificity, toxicology and
      pharmacokinetics of the Company&#8217;s lead HCV molecules. In these studies, when
      administered orally to rodents, the compounds demonstrated preferential
      accumulation in the liver in concentrations that were orders of magnitude above
      those required to block viral replication as predicted by the replicon assay,
      with half-lives consistent with a twice a day dosing regimen. Toxicology studies
      showed that the activity of these molecules was selective for HCV, with no
      apparent adverse effects on a range of human cell types or on rodents exposed
      to
      repeated high doses.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      small
      molecules being presented by the Company at the conference emerged from the
      Company&#8217;s DOS program, aimed at discovering novel HCV inhibitors by applying a
      unique chemistry technology called Diversity Oriented Synthesis. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      HEPATITIS C VIRUS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      are
      approximately 3 million people infected with HCV in the U.S. alone. HCV
      infection significantly increases the infected person&#8217;s risk of developing
      chronic liver disease, cirrhosis and liver cancer, and is the leading cause
      of
      liver transplantation in the Western World. HCV infection remains a major unmet
      medical need as the current standard of care (interferon-based therapy) achieves
      success in only 50% of patients infected with genotype 1 of the virus (genotype
      1 affects 75% patients in the U.S.), and has significant side affects associated
      with it.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine,
      a
      serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic
      neuropathic pain, which is currently in a Phase 2b study. XTL is also developing
      novel pre-clinical HCV small molecule inhibitors. XTL also has an active
      in-licensing and acquisition program designed to identify and acquire additional
      drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock
      Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future performance and prospects of our pre-clinical compounds
      for
      HCV from our XTL-DOS program, may be forward-looking statements that involve
      a
      number of risks and uncertainties. For those statements, we claim the protection
      of the safe harbor for forward-looking statements contained in the Private
      Securities Litigation Reform Act of 1995. Among the factors that could cause
      our
      actual results to differ materially are the following: our ability to
      successfully complete the pre-clinical development DOS program; our ability
      to
      clinically develop candidates from the DOS program; and other risk factors
      identified from time to time in our reports filed with the Securities and
      Exchange Commission, including our annual report on Form 20-F filed with the
      Securities and Exchange Commission on March 23, 2007. Any forward-looking
      statements set forth in this press release speak only as of the date of this
      press release. We do not intend to update any of these forward-looking
      statements to reflect events or circumstances that occur after the date hereof.
      This press release and prior releases are available at http://www.xtlbio.com.
      The information in our website is not incorporated by reference into this press
      release and is included as an inactive textual reference only.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;December
              10, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="45%"><font size="2">Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive
                Officer</font>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>v096825_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v096825_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!%`-$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BN1^(C>
M(;;PU)J/AR_>WN;,&66)8XW$L>/F^^IP5`R,'GD8)(QX7_PMCQO_`-!QO_`:
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MZLTFDVV8@@BB4RS$`X.$S@*<]1R5Z\URSPTH1YI,Z8XB,I<L4>LT5\X^)/B=
MXPL/%.KV=MK)CM[>]FBB3[/$=JJY`&2N>@K+_P"%L>-_^@XW_@-#_P#$5:P<
MVKW1+Q4$[69]145\N_\`"V/&_P#T'&_\!H?_`(BC_A;'C?\`Z#C?^`T/_P`1
M1]2J=T+ZW#LSZBHKY=_X6QXW_P"@XW_@-#_\11_PMCQO_P!!QO\`P&A_^(H^
MI5.Z#ZW#LSZBHKRWX/>+-;\4-K/]LWQNOLX@\K,:)MW>9G[H&?NCKZ5ZE7/4
M@X2<6;PFIQYD%%%<KX]U>^T?1H)["<PRM<!&8*&R-K''(/H**=-U)J"ZDUZR
MHTW4ELCJJ*Y?P'JU[K&AS7%_.9I5N60,5"\!5../J:ZBBI3=.;@^@4*RK4U4
MCLPHHH[5!J%%>0:SXQU^WUS4+:WU%DBCN9(T`C0[0&(`Z5Z\.E;UJ$J48R?4
MY,-C(8B4XQ37*[?G_D+1116!UA1110`4444`!&1BOF3XI^#_`/A%O$QFMD"Z
M=J!::W"@`1MGYXP!T`)&.,8('.#7TW6%XP\-0>+/#5UI4V%=QO@E(!,<@Y4]
M#CT..<$CO6U"K[.=^AC6I^TC;J?/?PP\5GPOXMA\^79I]Z1!<Y.`N3\KG)`&
MT]2<X4MQ7??&SQ@L-JGABRFS-+MDO2C`[4ZJAXX).&['`'4-7BEY:3Z??7%E
M=1^7<6\C12ID':RG!&1P>1VI+JZN+VX:XN[B6>9@`TDKEF.!@9)YX``_"O2E
M1C*HJAP*K*,'`O>'="NO$NOVFDV@Q)</@N>B*.68_0`G'?IUKZRT72+70=&M
M=+LE*V]M&$7.,MZL<`#).23ZDUQ'PF\#GPUHIU.^C*ZI?H"R.@!@C[)Z@G@M
MT_A&/ER?1JX<56YY<JV1VX>ER1N]V<)??"/PKJ.H7-]<0W33W,KS2$3D#<Q)
M.!]34'_"EO!__/"[_P#`@UZ%16/M:G\S-?90[(^*J]<^%WP^T#Q9X8N+_5(I
MVGCO&A!CE*C:$0CC_@1KR.OH7X$?\B/>_P#82?\`]%Q5Z6*DXT[IGGX9)SLT
M7O\`A2W@_P#YX7?_`($&OG[Q%90Z;XFU6PMP1!;7DT,88Y.U7(&3]!7V'7R+
MXQ_Y'C7_`/L)7'_HQJQP<Y2;N[FN*A&*5D>G_L_=?$7_`&[?^U:]KKQ3]G[K
MXB_[=O\`VK7M=<V)_BO^NAOA_P"$@KA_BA_R+]M_U]+_`.@/7<5P_P`4/^1?
MMO\`KZ7_`-`>GA/X\?4PS+_=*GH+\,Y$C\+W3NP51=N22<`?(E;$_C7P[;S-
M$^IQEEZF-6<?@5!!_"O*])_M76+>/P[8<0R3&:3&0.@&7/\`=&!^/J<5UB_"
MH[!NUCYL<XM^!_X]7;7H454<JTK7Z(\S"8K%.A&&&IW26K??RU1W6GZM8:K&
M9+&[BG``+!&Y7/3(ZC\:NUXEJ^C:GX-U2WF6<9+%H)XCC.#R".W!&1R.>_->
MH^%-=_X2#1([MU5+A6,<R*<@,.X]B,'VSCM7-B,*J<54@[Q9WX/'NM-T:L>6
M:Z$UQ>^'X9Y$N;C34F!^=9'C#9]P><UK#D5X;XK_`.1PO_\`KM_05[-J6HP:
M5IT][<$B*)2QVXR?0#/<G`%37P_)&#B[\W_`'A,;[655222@_P#/_(GN;F"S
M@:>YFCAB7&YY&"J,G')/UK#D\<>'(Y&1M24D':=L;L/S`P1[UYG-<:QXXUU8
MEY8Y*1YQ'"F>2?TR>IX]A761?"RU%NXEU.9IS]QDC"J/J,DG\Q6SPM&DDJTM
M>R.:.88G$-O"TTXKJ^OY':6&K:?JB%K&\AGP`S!'!*@],CJ.AZ^E7:\5USP]
MJ?@Z_AN8KAFCS^ZNH@5PV.01V/7CN/Q`](\'^)!XATQFEP+R`A9E48'.<$?4
M#\P:SKX50@JE-WB;X3'NI4="M'EFOQ.BHHHKC/3"D)"C)('UI:\E^,_C7^S]
M._X1JQD7[3=IFZ=78-%%QA>./GY!R?N@Y'S`U=.#G)11%2:A%R9Y9\0O$-IX
MF\8W>H6,2);86..0(5:8*,;VSW/;I\H48R*YJ&5H)XYD"%D8,`Z!UR#GE6!!
M'L00:M:1I5UK>K6NF62;[BYD$:#!(&>I.`<`#))[`$UT?Q$\%-X+UU((6DDT
M^XC#V\LC`L2``X;``R#SP.C+WKV%RQM3/+:E*\SZ*\)>)+7Q9X=MM5MALWY6
M6$N&,4@ZJ<?F.F00<#-;=?,WPL\9MX6\1K;74C?V7?,L<P)`6-\X63GH!T/(
MX.><"OIGK7E5Z7LY6Z'I4:GM(WZA1116)J?%5?0OP(_Y$>]_["3_`/HN*OGJ
MOH7X$?\`(CWO_82?_P!%Q5ZN+_AGFX7^(>H5\B^,?^1XU_\`["5Q_P"C&KZZ
MKY%\8_\`(\:__P!A*X_]&-7/@OB9MC/A1Z?^S]U\1?\`;M_[5KVNO%/V?NOB
M+_MV_P#:M>UUCB?XK_KH:X?^$@KA_BA_R+]M_P!?2_\`H#UW%</\4/\`D7[;
M_KZ7_P!`>GA/X\?4PS+_`'2IZ%;X6V*K97VH':7>00#*\J%`8X/ON''^R*]!
MKBOA@V?#5R,$8NV_'Y$KM:>,;=>5Q99%1PD+=CEOB#;I-X1NI'3<T+1NG/W3
MO"D_DQKE?A=<E-9OK4(,2P"0ODY&QL`?^/FNO\>G'@R_[9\O_P!&+7'_``NA
M<ZW>7`7,:6^QFST+,"!_XZ?RKIH?[G.^U_\`(X<5IFE+EWM_F8/BO_D;[_\`
MZ[#^0KM/BA>M%IUC9*#B>1G9@W9`.,=\[L_A7%^*_P#D;[__`*[#^0KK?BI$
MYBTN8*=BM*K'T)VD?R/Y5TV3G0OV_1'"FU1Q=NZ_-EOX86"1Z/<WQ0B2:;8&
M/=5`Z?B3^5=U7(?#BZ\[PJL1`'D3O&,=\X;)_P"^JZ^O,Q;;KROW/>RY16%I
M\O;_`(<R?$]FE[X9U&%H_,/D.Z*.I91E?U`KS+X=W;6_BV&)5!%S$\39[`#=
MG_QW]:]8U.Z^Q:5>70`)AA>0`]#A2?Z5Y#X!C=_&5DR(6""1G('W1L89/XD#
M\:ZL)KAZB>W_``#S\RTQM!QWO^%U_P`$]IHHHKS3W3&\4>(K3PMH%SJET5/E
MKB*(OM,LASM0=>3]#@9/:OD_5=3NM9U6YU*]E:2XN)"[L23]`/8#``[``5]/
M^+_`EEXT>W&HZAJ$4%N#L@MW14W'JQRA)...O'8#)SS'_"B/#'_00U?_`+^Q
M?_&Z[,/5ITU=[G)7IU*CLMBI\$_"!L=/E\1WL.VXNAY=J'4@K%W8<_Q'';HO
M!PU=MX\\*IXN\+7&GAD2Y0B:VD?.%D7.,X[$%AWQG.#BNB@@BMK>.""-(XHE
M"(B*%55`P``.``.U25A.K*4^<WC348<A\6S0RV\\D,T;Q2QL4>-U(96!P00>
MA!KZ#^#GC+^V=#.B7DN;W3U`B)P-\'`7IU*_=/'3;U)-7]=^#_AW7M:NM4FG
MOK>6Y;>\=LT:INP,G!0\D\DYY))I-#^$.B>'M:M=6L=1U07-L^Y=[Q%2""""
M/+Z$$CUYX(KJJUZ=6%GN<U*C4ISNMCT&BBCM7`=I\55]"_`C_D1[W_L)/_Z+
MBI/^%$>&?^@AJ_\`W]C_`/C==GX2\)V/@W2I=.T^:XEBDG,Y:X92VXJJX^4#
MC"BN[$8B$X<L3BH4)PG=F]7R+XQ_Y'C7_P#L)7'_`*,:OKJO.-2^"_AW5=5O
M-1GOM466ZG>=U26/:&9BQQE.F366&JQIMN1KB*<JB2B>)>%_&FL>$/M7]DR1
M)]JV>9YD>[.W=C'I]XUT'_"Z/&'_`#WM/_`<5Z'_`,*(\,_]!#5_^_L?_P`;
MH_X41X9_Z"&K_P#?V/\`^-UTNOAV[M?@<ZHUTK)_B>>?\+H\8?\`/>T_\!Q3
MD^(&N^+&^PZI)`T,8\Y?+B"G<..OT8UZ#_PHCPS_`-!#5_\`O['_`/&ZM6/P
M7\/:=,TL-]J99EV_/)&1CKV0>E53KX>,E*WX&6)PV(J4I03W\S!\&^(SX<OM
MMVC_`&&[`+-@_+@D!P.XZ@X_IBO4(_$NARQJZZM9!6`(W3JI_$$Y%4)/!.ES
M:%!I4IE:.`LT4V1YBDDD\XQWZ8]/3-<V?A4V>-8&/^O;_P"RJ:D\-7DY2;B_
MS.>A3Q^#@J<(J:]=NZ,SQSXL@UORK&P+/:QMYC2D$;VP0,`\X&3UZ_ASV'@'
M0Y-(T-I;E-ES=-YC*5P57'RJ>?J>V-V.U,T/X?:;I-S%=SRO>7,1RN\!4![$
M+ZCW)]>N,==6>(KT_9JC1V_,WP>#K.L\5B?BZ)=#PWQ7_P`C??\`_78?R%>K
M>*]$&O:#-;*/W\9\V`YQ\X!XZ@<@D<],Y[5GZC\/],U/4YK^:YNUDE;<51EV
MC\UKJP,4J^)35/DWC_P`PF!E%UE56DW^&IXOX2\0-X7U>87L<PMI1LGCV?,C
M#.#@C.1D@CW]17J</B?0IX5E35K,*PR`\RHWX@D$?C537_!NF:^S32*T%V1@
M3Q]\#C<.A[>_&,URX^%3]]94^_V;_P"SK6I/#8A\\FXLQI4L=@_W=.*G'IK:
MQ%XY\8VVH6G]EZ7*TB,P,\H'RL!_",C)YP<C'3OFM#X;:%):VTFKW",C7"[(
M58$'9D'=]"0,9';(X-6M'^&^FV$PGOIGOG5LHA79&.A&1DDG(/4X(."#7:8Q
M45L13C2]C1VZLUPV#K3K_6<5NMDN@4445P'KA1110`4444`%%%%`!1110`44
I44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
